441 related articles for article (PubMed ID: 25027316)
1. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
[TBL] [Abstract][Full Text] [Related]
2. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy.
Hanada T; Hashizume Y; Tokuhara N; Takenaka O; Kohmura N; Ogasawara A; Hatakeyama S; Ohgoh M; Ueno M; Nishizawa Y
Epilepsia; 2011 Jul; 52(7):1331-40. PubMed ID: 21635236
[TBL] [Abstract][Full Text] [Related]
3. Development of perampanel in epilepsy.
Satlin A; Kramer LD; Laurenza A
Acta Neurol Scand Suppl; 2013; (197):3-8. PubMed ID: 23480150
[TBL] [Abstract][Full Text] [Related]
4. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
Rektor I
Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
[TBL] [Abstract][Full Text] [Related]
5. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel.
Zaccara G; Giovannelli F; Cincotta M; Iudice A
Expert Rev Neurother; 2013 Jun; 13(6):647-55. PubMed ID: 23739002
[TBL] [Abstract][Full Text] [Related]
6. The discovery and development of perampanel for the treatment of epilepsy.
Hanada T
Expert Opin Drug Discov; 2014 Apr; 9(4):449-58. PubMed ID: 24559052
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist.
Hibi S; Ueno K; Nagato S; Kawano K; Ito K; Norimine Y; Takenaka O; Hanada T; Yonaga M
J Med Chem; 2012 Dec; 55(23):10584-600. PubMed ID: 23181587
[TBL] [Abstract][Full Text] [Related]
8. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy.
El Desoky ES
Fundam Clin Pharmacol; 2014 Oct; 28(5):473-80. PubMed ID: 24750493
[TBL] [Abstract][Full Text] [Related]
9. Introduction: Perampanel--new mode of action and new option for patients with epilepsy.
Steinhoff BJ
Epilepsia; 2014 Jan; 55 Suppl 1():1-2. PubMed ID: 24400689
[TBL] [Abstract][Full Text] [Related]
10. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
Krauss GL; Perucca E; Ben-Menachem E; Kwan P; Shih JJ; Squillacote D; Yang H; Gee M; Zhu J; Laurenza A
Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
[TBL] [Abstract][Full Text] [Related]
11. The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy.
Twele F; Bankstahl M; Klein S; Römermann K; Löscher W
Neuropharmacology; 2015 Aug; 95():234-42. PubMed ID: 25839899
[TBL] [Abstract][Full Text] [Related]
12. Perampanel and decanoic acid show synergistic action against AMPA receptors and seizures.
Augustin K; Williams S; Cunningham M; Devlin AM; Friedrich M; Jayasekera A; Hussain MA; Holliman D; Mitchell P; Jenkins A; Chen PE; Walker MC; Williams RSB
Epilepsia; 2018 Nov; 59(11):e172-e178. PubMed ID: 30324610
[TBL] [Abstract][Full Text] [Related]
13. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives.
Di Bonaventura C; Labate A; Maschio M; Meletti S; Russo E
Expert Opin Pharmacother; 2017 Nov; 18(16):1751-1764. PubMed ID: 29023170
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatography-tandem mass spectrometry method for the determination of perampanel, a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist in human plasma.
Mano Y; Takenaka O; Kusano K
J Pharm Biomed Anal; 2015 Mar; 107():56-62. PubMed ID: 25569285
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of calcium-permeable and calcium-impermeable AMPA receptors by perampanel in rat brain neurons.
Barygin OI
Neurosci Lett; 2016 Oct; 633():146-151. PubMed ID: 27663136
[TBL] [Abstract][Full Text] [Related]
16. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.
Patsalos PN
Epilepsia; 2015 Jan; 56(1):12-27. PubMed ID: 25495693
[TBL] [Abstract][Full Text] [Related]
17. Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy.
Russmann V; Salvamoser JD; Rettenbeck ML; Komori T; Potschka H
Epilepsia; 2016 Apr; 57(4):638-47. PubMed ID: 26854031
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
19. BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties.
Weiser T; Brenner M; Palluk R; Bechtel WD; Ceci A; Brambilla A; Ensinger HA; Sagrada A; Wienrich M
J Pharmacol Exp Ther; 1999 Jun; 289(3):1343-9. PubMed ID: 10336525
[TBL] [Abstract][Full Text] [Related]
20. The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia.
Brito da Silva A; Pennifold J; Henley B; Chatterjee K; Bateman D; Whittaker RW; Joshi A; Kumar H; Nicholson C; Baker MR; Greenhill SD; Walsh R; Seri S; Jones RSG; Woodhall GL; Cunningham MO
Epilepsia Open; 2022 Sep; 7(3):488-495. PubMed ID: 34653311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
